Inmune Bio Inc Stock Price, News & Analysis

INmune Bio Inc. (NASDAQ: INMB) announced Q2 2024 results and provided a business update. Key highlights include:

1. The Phase 2 trial for XPro™ in Early Alzheimer's Disease is on track to complete enrollment by Q3 end.
2. A new Phase 1b analysis shows XPro's™ significant effects on synaptic proteins.
3. INKmune™ platform progress includes a new formulation and completion of the first cohort in the Phase I/II trial for metastatic castration-resistant prostate cancer.
4. The company raised $14.5 million in equity capital.
5. Q2 2024 financial results: Net loss of $9.7 million, R&D expenses of $7.1 million, and cash position of $31.1 million as of June 30, 2024.

INmune Bio (NASDAQ: INMB) presented new Phase 1 study data at the Alzheimer's Association International Conference, demonstrating XPro's™ dose-dependent effect on synaptic proteins in Alzheimer's patients. The 12-week treatment resulted in significant changes to proteins essential for neuron communication. This aligns with preclinical models and supports the restoration of normal immune function.

The company's VP of Neuroscience, CJ Barnum, emphasized the importance of these findings, as synaptic loss is an early and devastating consequence of Alzheimer's. CEO RJ Tesi highlighted that this cellular-level evidence supports recent EEG data showing improved synaptic function. INmune Bio is currently conducting a Phase 2 trial for mild to moderate Alzheimer's, with top-line results expected in early 2025.

INmune Bio Inc. (NASDAQ: INMB), a clinical-stage immunology company, has announced its upcoming second quarter 2024 financial results and corporate update conference call. The event is scheduled for Thursday, August 1, 2024, at 4:30 PM EDT. Investors and interested parties can participate via phone or live audio webcast. The call will cover results for the quarter ended June 30, 2024, and provide insights into the company's current operations and future plans. A replay of the call will be available until August 8, 2024, and a transcript will be provided approximately 24 hours after the scheduled call.

INmune Bio Inc. (NASDAQ: INMB) has published a landmark paper in the Journal for ImmunoTherapy of Cancer, detailing the biology of their Natural Killer cancer immunotherapy, INKmune™. The study demonstrates that memory-like natural killer (mlNK) cells, generated by either cytokine or INKmune™ priming, show increased cytotoxicity against multiple tumor types. Notably, mlNK cells from cancer patients are as potent as those from healthy volunteers, supporting INKmune's in vivo treatment approach.

The research provides insights into NK cell memory mechanisms, potentially leading to innovative treatments for hematological malignancies and solid tumors. INKmune™ priming increases proteins that protect NK cells in the tumor microenvironment, which is promising for their ongoing clinical trial in metastatic castration-resistant prostate cancer. The study also demonstrates in vivo generation of mlNK cells and their enhanced metabolic function, suggesting improved performance in the tumor microenvironment.

INmune Bio (NASDAQ: INMB) has completed a blinded interim analysis of its Phase II Alzheimer’s Disease (AD) trial, AD02. The trial uses the Early Mild Alzheimer’s Cognitive Composite (EMACC) as its primary endpoint. The analysis, conducted by third-party statisticians and neuropsychologists, confirmed the trial’s design, operational execution, and data management are of high quality. The interim results showed no need to change the trial design or sample size, reinforcing the EMACC's suitability in measuring cognitive changes in early AD. EMACC was chosen for its objective and validated cognitive measures, previously demonstrated in Biogen studies, and its strong association with biological markers of inflammation. Dr. CJ Barnum, VP of Neuroscience, endorsed the positive findings, along with consultants Dr. Paul Maruff and Dr. Judith Jaeger, citing the EMACC’s high acceptability and reliability in detecting cognitive changes in patients with early AD.

INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, will join the Russell 3000® Index following the 2024 Russell US Indexes annual reconstitution. Effective July 1, the inclusion is based on market capitalization rankings as of April 30. This membership also means automatic inclusion in either the Russell 1000® or Russell 2000® Index, and relevant growth and value style indexes, lasting one year. CEO Dr. Raymond J. Tesi believes this will boost the company's visibility and attract more investors. The Russell indexes, used by investment managers for benchmark strategies, reflect $10.5 trillion in assets.

INmune Bio Inc. announced its first-quarter 2024 financial results and provided a business update, highlighting milestones in their DN-TNF, INB03 cancer, and INKmune platforms. The company raised $14.5 million in equity capital, completed the first dosing in a Phase I/II trial of INKmune for mCRPC, and disclosed a net loss of $11.0 million for the quarter ended March 31, 2024.

INmune Bio Inc. will report its first quarter 2024 financial results and provide a corporate update on May 9. The clinical-stage immunology company is focused on developing treatments leveraging a patient's innate immune system to combat diseases. A conference call and webcast will be hosted at 4:30 PM ET on the same day.

INmune Bio Inc. provides an update on two patients from the Phase 1b Alzheimer’s Disease Trial who have been receiving XPro™ for over three years under the Australian compassionate use program. Both patients have shown stable cognitive function and a desire to continue treatment. The long-term administration of XPro™ has been safe and well-tolerated, according to primary care physicians.